Biocon Biologics partners Adagio Therapeutics for Covid-19 treatment

As a part of the deal with Adagio, the company would get access to the clinical and non-clinical data from Adagio’s EUA submission to the US Food and Drug Administration to seek approvals in the emerging markets.

from The Financial Express https://ift.tt/3zKu4Vx
https://ift.tt/eA8V8J FE Bureau